Favorable Adherence and Tolerability of Letermovir Versus Valganciclovir for Cytomegalovirus Prophylaxis in Kidney Transplant Recipients Aged 65 y or Older: Findings From a Randomized, Phase 3 Trial. (PubMed, Transplant Direct) - Aug 26, 2026 - P3 | "Letermovir showed substantial advantages over valganciclovir in adherence, safety, and tolerability, supporting its use as an important option for cytomegalovirus disease prophylaxis for older patients undergoing kidney transplantation. ClinicalTrials.gov, NCT03443869."
Clinical • Journal • P3 data • Cytomegalovirus Infection • Hematological Disorders • Infectious Disease • Leukopenia • Neutropenia • Transplantation
|
|
Barbara Haber; Christopher L Gilbert; Flavio Vincenti; M Hong Nguyen; Natalya Broyde; Oliver Witzke; Stefan Schneeberger; Suphamai Bunnapradist
|